Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome

Medicus Pharma (NASDAQ:MDCX) said Monday it has submitted a Rare Pediatric Disease Designation request to the US Food and ...
Medscape

Curettage Plus Imiquimod Less Effective Than Surgery for Nodular BCC

In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC). At 5 years ...
TMCnet

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

In addition, if Orphan Drug Designation is granted and a future marketing application is approved, SkinJect® may become eligible for seven years of U.S. market exclusivity for the designated ...
Healio

Superficial curettage, imiquimod cream 5% sees more failure at 5 years in nodular BCC

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Five years after treatment, results showed a freedom ...
Nasdaq

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA) PHILADELPHIA, Feb. 14, 2025 (GLOBE ...
Health on MSN

What does skin cancer look like?

Medically reviewed by Katlein Franca, MD Basal cell carcinoma often appears as a shiny bump or red patch on sun-exposed ...
Nasdaq

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) The Company also announced that it is ...